The percentage of patients in whom cancer was detected within 3 years of DM diagnosis decreased from 30% in those with autoantibodies against TIF1-γ alone, to 15%, 3%, and zero in patients with 1, 2, or more than 2 additional autoantibody specificities, respectively. This evidence concerns the gene TRIM33 and cancer.